Precigen (PGEN) Capital Expenditures (2012 - 2026)
Precigen (PGEN) reported Capital Expenditures of $258000.0 for Q1 2026, down 58.52% year-over-year from $622000.0 in Q1 2025, and up 201.57% quarter-over-quarter from -$254000.0 in Q4 2025.
Precigen (PGEN) Capital Expenditures (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Capital Expenditures data on file, last reported at $258000.0 in Q1 2026.
- Capital Expenditures for Q1 2026 came in at $258000.0, down 58.52% year-over-year; the trailing twelve-month figure through Mar 2026 was -$150000.0 (down 102.11% YoY), and the FY2025 annual result was $214000.0, down 97.51% from the prior year.
- Capital Expenditures grew to $258000.0 in Q1 2026 per PGEN's latest filing, from -$254000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $7.9 million in Q4 2024 and troughed at -$5.9 million in Q3 2024.
- A 5-year average of $855647.1 and a median of $251000.0 in 2022 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2022 and 2024: Capital Expenditures plunged 3231.18% in 2022, then surged 10368.0% in 2024.
- A 5-year view of Capital Expenditures shows it stood at $4.7 million in 2022, then tumbled by 98.41% to $75000.0 in 2023, then surged by 10368.0% to $7.9 million in 2024, then sank by 103.24% to -$254000.0 in 2025, then surged by 201.57% to $258000.0 in 2026.
- Business Quant data shows PGEN's Capital Expenditures at $258000.0 in Q1 2026, -$254000.0 in Q4 2025, and -$1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -63,220.27 |
| 10 | Precigen | 1.32 Bn | 1.32 Bn | 20.69 Mn | 258,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 258,000.00 |
| Mar 31, 2026 | 258,000.00 |
| Dec 31, 2025 | -254,000.00 |
| Dec 31, 2025 | -254,000.00 |
| Sep 30, 2025 | -1.12 Mn |
| Sep 30, 2025 | -1.12 Mn |
| Jun 30, 2025 | 966,000.00 |
| Jun 30, 2025 | 966,000.00 |
| Mar 31, 2025 | 622,000.00 |
| Mar 31, 2025 | 622,000.00 |
| Dec 31, 2024 | 7.85 Mn |
| Dec 31, 2024 | 7.85 Mn |
| Sep 30, 2024 | -5.94 Mn |
| Sep 30, 2024 | -5.94 Mn |
| Jun 30, 2024 | 4.57 Mn |
| Jun 30, 2024 | 4.57 Mn |
| Mar 31, 2024 | 2.11 Mn |
| Mar 31, 2024 | 2.11 Mn |
| Dec 31, 2023 | 75,000.00 |
| Dec 31, 2023 | 75,000.00 |